Unseen Upside S4:EP4 Appetite for Change: The Obesity Epidemic Meets Biotech

Published on February 26, 2024

Obesity is a global health crisis, with over 650 million adults affected worldwide. This drives massive economic and disease burdens. Yet new treatment options like GLP-1 drugs offer hope. This episode analyzes the landscape and future of obesity therapeutics, focusing on transformational GLP-1 drugs like Ozempic that curb appetite. Join us as we investigate the promise and challenges of emerging anti-obesity drugs, learn about one patient’s journey taking them, and discover what the future of weight loss medicine could look like. We’ll hear from Rod Wong (RTW Investments); Dean Dimizas (Cambridge Associates); Raymond Stevens, Ph.D. (Structure Therapeutics); and Kathleen Mikaelian (patient).

 

Listen to episode four here.

Other news

Unseen Upside S4:EP5 Unlocking the Dark Genome for Lupus & Other Autoimmune Diseases

February 26, 2024
Autoimmune diseases like lupus impact over 5 million patients globally, but treatment options remain limited. Now, decoding the once mysterious "dark genome" could bring new therapies. Over 90% of our DNA was once considered "junk"—but we’ve learned this dark matter regulates gene expression and human disease. This episode takes you to the pioneers who are unlocking the dark genome's potential to

Unseen Upside S4:EP6 AI & Healthcare: The Next Frontier

February 26, 2024
Artificial intelligence is transforming healthcare, unleashing new investment opportunities. From cancer screening to chronic disease management, AI promises to augment clinical decision-making and improve care. We’ll explore the surging ecosystem of medical AI innovations, from the emerging tech landscape to practical deployment. What are the challenges facing real-world implementation? Which app